2 ASX shares experts think have sold off too much

Which stocks have seen their value plummet even though the underlying businesses have not changed one iota? This pair.

| More on:
A man in a business suit wearing boxing gloves slumps in the corner of a boxing ring representing the beaten-up Zip share price in recent times

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's shocking enough the S&P/ASX 200 Index (ASX: XJO) has sunk 5.8% so far this year.

But with mining and financial shares dragging the index up, there are hundreds of ASX shares that have fallen far more than that.

Some former market darlings, especially ASX growth stocks, have seen their valuations halve, if not worse.

But are we now at a point where some of those businesses have been punished too much? Perhaps the stock price has lost all sense of the company's outlook?  

A couple of experts recently each picked out an ASX share they think are in that position and are ripe to buy right now:

'Unjustly' sold off

To Montgomery Investment Management portfolio manager Gary Rollo, Symbio Holdings Ltd (ASX: SYM) looks way too cheap at the moment.

The software maker has seen its share price plunge 38.7% this calendar year.

"It's been sold off so hard because the comparators, the overseas players that do what it does, they're at a different stage in their life cycle than the Symbio is," Rollo told a Livewire video.

"So this business has had its valuation regime adjusted, I think unjustly, without reflecting on the fundamentals."

Rollo doesn't detect any change to the business or its outlook compared to before the stock price fall.

"It's a $350 million market cap. It's got $50 million of cash on the balance sheet, so we don't have a capital structure question," he said.

"It's on 8.5 to 9 times EBITDA [earnings before interest, tax, depreciation, and amortisation]… so it doesn't have a valuation question."

Symbio's hot growth opportunity is in Asia and that hasn't diminished.

"But you're not paying for it and so we like the look of that and that's our tip for now." 

'Capital-light, high growth' business

QVG Capital portfolio manager Josh Clark picked Johns Lyng Group Ltd (ASX: JLG) as a current bargain.

Johns Lyng shares have fallen a shocking 37.5% just this month.

"Yeah, absolutely it's been sold off, [from] the $9 range into the mid-$5s or thereabouts, so the valuation's actually starting to look much more compelling."

As a service provider to insurance companies, Johns Lyng was recognised by the market as a star in recent years.

Clark admits that did make the ASX share expensive before May started.

"But they haven't seen a change to their earnings. They're still going to hit their earnings guidance," he said.

"I think part of the sell-off is the market's having a bit of a hissy fit that there's no upgrade near term… Also management has sold some stock."

Clark urged investors to look past the recent share price movements.

"If you focus too much on that, you're missing the forest for the trees," he said.

"It's still a really capital-light, high growth services business. I've said this a lot, but owner, founder-led, which is really important and these guys have just got more irons in the fire than you can count."

Motley Fool contributor Tony Yoo has positions in Johns Lyng Group Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Johns Lyng Group Limited and Symbio Holdings Limited. The Motley Fool Australia has positions in and has recommended Symbio Holdings Limited. The Motley Fool Australia has recommended Johns Lyng Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Broker looking at the share price.
Broker Notes

Broker ratings on 6 ASX shares about to join the ASX 200

These 6 companies will enter the ASX 200 in the December quarter rebalance. Should you buy them?

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Broker Notes

3 reasons this ASX 300 tech stock is forecast to leap 83% in 2026

A leading broker expects some outsized returns from this ASX 300 tech share. Let’s see why.

Read more »

gold share price represented by speeding golden bullet
Broker Notes

Why this surging ASX All Ords gold stock is tipped to rocket another 233%

A leading broker expects outsized gains from this ASX All Ords gold stock. But not without risk.

Read more »

A blockchain investor sits at his desk with a laptop computer open and a phone checking information from a booklet in a home office setting.
Broker Notes

3 buy-rated ASX 300 shares at 52-week lows

They've fallen far over the past 12 months but have buy ratings from the experts.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Broker Notes

Bell Potter names more of the best ASX 200 shares to buy in December

These are best buys according to the broker. Here's what it is saying about them.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 30% to 40% in 2026

Looking for big returns? Analysts think these shares could beat the market.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Broker Notes

Analysts name 3 ASX shares to buy this week

Analysts have good things to say about these shares.

Read more »